Trivascular Technologies (NASDAQ: TRIV) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it contrast to its rivals? We will compare Trivascular Technologies to related companies based on the strength of its analyst recommendations, risk, institutional ownership, valuation, earnings, dividends and profitability.
This is a breakdown of recent ratings and recommmendations for Trivascular Technologies and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Trivascular Technologies Competitors||127||739||1041||10||2.49|
Insider and Institutional Ownership
54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares Trivascular Technologies and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Trivascular Technologies Competitors||$1.67 billion||$207.76 million||50.15|
Trivascular Technologies’ rivals have higher revenue and earnings than Trivascular Technologies. Trivascular Technologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This table compares Trivascular Technologies and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Trivascular Technologies Competitors||-100.14%||-92.44%||-29.75%|
Trivascular Technologies rivals beat Trivascular Technologies on 8 of the 8 factors compared.
About Trivascular Technologies
Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.
Receive News & Ratings for Trivascular Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trivascular Technologies and related companies with MarketBeat.com's FREE daily email newsletter.